Zejula
Niraparib · GlaxoSmithKline LLC
CANCER MEDICINE · PRESCRIPTION ONLY (USA)Zejula ingredients
| Active ingredient | Strength |
|---|---|
| Niraparib Tosylate | 300 mg/1, 100 mg/1, 200 mg/1 |
What Zejula is used for
Zejula is a cancer medicine (poly(adp-ribose) polymerase inhibitor). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Zejula
- Generic name
- Niraparib
- Made by
- GlaxoSmithKline LLC
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Poly(ADP-Ribose) Polymerase Inhibitor
- FDA approval
- New drug application (NDA) NDA214876
- On the US market since
- 2023
Official information
- Zejula prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Niraparib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zejula?
Zejula (Niraparib) is a cancer medicine made by GlaxoSmithKline LLC, approved by the US FDA.
What are the ingredients of Zejula?
Zejula contains Niraparib Tosylate (300 mg/1, 100 mg/1, 200 mg/1).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA